Skip to main content
. 2024 Sep 3;14:20489. doi: 10.1038/s41598-024-68150-y

Figure 1.

Figure 1

Metastasis in the metastatic group versus the non-metastatic group and survival analysis between the two groups. (A)The study included 324 CRC patients, comprising 123 metastatic patients (38.0%) and 201 non-metastatic patients (62.0%). (B) The OS in the CRC group with distant metastasis decreased by 19.96 months compared to the non-distant metastasis group (33.83 ± 1.92 months vs. 53.79 ± 1.01 months), with a statistical significance of P < 0.001. (C) The PFS in the CRC group with distant metastasis decreased by 31.83 months compared to the non-distant metastasis group (19.56 ± 1.49 months vs. 51.39 ± 1.13 months), with a statistically significant difference of P < 0.001.